Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Claire GalloisQian ShiLevi D PedersonThierry AndréTimothy J IvesonAlberto F SobreroSteven R AlbertsAimery deGramontJeffrey A MeyerhardtThomas J GeorgeHans-Joachim E SchmollIoannis SouglakosAndrea HarkinRoberto LabiancaFrank A SinicropeEiji OkiAnthony Frank ShieldsIoannis BoukovinasRachel KerrSara LonardiGreg YothersTakayuki YoshinoRichard M GoldbergGilles ManceauDemetris PapamichaelPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
In patients ≥70 years with stage III CC fit enough to be enrolled in clinical trials, oxaliplatin-based adjuvant chemotherapy was well tolerated and led to similar TTR compared with younger patients, suggesting similar efficacy. TTR may be a more appropriate end point for efficacy in this patient population.